Clinical Trial

Comparing Antipsychotic Medications in LBD Over Time

Study acronym: CAMELOT
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to determine whether treatment with pimavanserin or quetiapine is associated with a greater improvement in psychosis when used in a routine clinical setting to treat hallucinations and/or delusions due to Parkinson's disease (PD) or dementia with Lewy bodies (DLB) - collectively referred to as Lewy body disease (LBD).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-10-18; most recent amendment 2025-09-08.
Trial Details
NCT Number NCT05590637
Lead Sponsor The University of Texas Health Science Center at San Antonio
Collaborators: Alzheimer's Association
Conditions Parkinson's Disease Psychosis, Dementia With Lewy Bodies
Enrollment 94 participants
Start Date 2022-04-22
Primary Completion 2026-08 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2025-09-09